Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeWages, Salaries and Other
Others
Ratios

Sagimet Biosciences (SGMT) EBITDA (2023 - 2024)

Sagimet Biosciences has reported EBITDA over the past 2 years, most recently at -$16.4 million for Q4 2024.

  • Quarterly results put EBITDA at -$16.4 million for Q4 2024, down 102.09% from a year ago — trailing twelve months through Dec 2024 was -$45.4 million (down 63.41% YoY), and the annual figure for FY2025 was -$51.1 million, down 12.74%.
  • EBITDA for Q4 2024 was -$16.4 million at Sagimet Biosciences, down from -$14.2 million in the prior quarter.
  • Over the last five years, EBITDA for SGMT hit a ceiling of -$6.4 million in Q3 2023 and a floor of -$16.4 million in Q4 2024.